Stock Track | AtriCure Soars 13.44% After-Hours on Strong Q4 Earnings Beat and Positive 2026 Outlook

Stock Track

Feb 18

AtriCure's stock surged 13.44% in after-hours trading following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.

The surgical treatment innovator reported adjusted earnings per share of $0.06 for Q4 2025, beating the consensus estimate of a loss of $0.10 per share. Revenue for the quarter reached $140.5 million, also surpassing expectations. The company's adjusted EBITDA of $19.9 million substantially outperformed the estimated $13 million, while gross margin stood at a healthy 75%.

Looking ahead, AtriCure provided an optimistic outlook for 2026, projecting revenue between $600 million and $610 million and adjusted EPS in the range of $0.09 to $0.15. The company also expects continued positive cash generation throughout the year, fueling investor confidence in its growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1162616366"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162616366\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162616366?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162616366","market":"nz","top_or_hot":-1,"title":"Stock Track | AtriCure Soars 13.44% After-Hours on Strong Q4 Earnings Beat and Positive 2026 Outlook","media":"Stock Track","content":"<p>AtriCure's stock surged 13.44% in after-hours trading following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.</p><p>The surgical treatment innovator reported adjusted earnings per share of $0.06 for Q4 2025, beating the consensus estimate of a loss of $0.10 per share. Revenue for the quarter reached $140.5 million, also surpassing expectations. The company's adjusted EBITDA of $19.9 million substantially outperformed the estimated $13 million, while gross margin stood at a healthy 75%.</p><p>Looking ahead, AtriCure provided an optimistic outlook for 2026, projecting revenue between $600 million and $610 million and adjusted EPS in the range of $0.09 to $0.15. The company also expects continued positive cash generation throughout the year, fueling investor confidence in its growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AtriCure Soars 13.44% After-Hours on Strong Q4 Earnings Beat and Positive 2026 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AtriCure Soars 13.44% After-Hours on Strong Q4 Earnings Beat and Positive 2026 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-18 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AtriCure's stock surged 13.44% in after-hours trading following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.</p><p>The surgical treatment innovator reported adjusted earnings per share of $0.06 for Q4 2025, beating the consensus estimate of a loss of $0.10 per share. Revenue for the quarter reached $140.5 million, also surpassing expectations. The company's adjusted EBITDA of $19.9 million substantially outperformed the estimated $13 million, while gross margin stood at a healthy 75%.</p><p>Looking ahead, AtriCure provided an optimistic outlook for 2026, projecting revenue between $600 million and $610 million and adjusted EPS in the range of $0.09 to $0.15. The company also expects continued positive cash generation throughout the year, fueling investor confidence in its growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATRC","symbol_name":"AtriCure公司","start_time":0,"source_url":"","article_id":"1162616366","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162616366","pubTimestamp":1771364211,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AtriCure's stock surged 13.44% in after-hours trading following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.The surgical treatment...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATRC":"AtriCure公司"},"translate_title":"股票追踪|AtriCure盘后飙升13.44%，第四季度盈利强劲，2026年前景乐观","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATRC":1},"content_text":"AtriCure's stock surged 13.44% in after-hours trading following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.The surgical treatment innovator reported adjusted earnings per share of $0.06 for Q4 2025, beating the consensus estimate of a loss of $0.10 per share. Revenue for the quarter reached $140.5 million, also surpassing expectations. The company's adjusted EBITDA of $19.9 million substantially outperformed the estimated $13 million, while gross margin stood at a healthy 75%.Looking ahead, AtriCure provided an optimistic outlook for 2026, projecting revenue between $600 million and $610 million and adjusted EPS in the range of $0.09 to $0.15. The company also expects continued positive cash generation throughout the year, fueling investor confidence in its growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}